Regulatory Story
Go to market news section View chart   Print
RNS
Evocutis PLC  -  EVO   

AGM Statement

Released 07:00 28-Jan-2013

RNS Number : 4215W
Evocutis PLC
28 January 2013
 



 

 

 

Press Release

28 January 2013

 

Evocutis plc

("Evocutis" or "the Company")

 

AGM Statement

 

Evocutis plc (AIM: EVO), the company focused on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, will be holding its Annual General Meeting at 12 noon today at IP Group, 24 Cornhill, London, EC3V 3ND.

 

Tom Bannatyne, Chairman, will provide the following trading update at today's meeting:

 

"In December last year, Evocutis announced that it had appointed consultants Growth Innovators Group and advisors Zeus Capital to assist the Company in reviewing and evaluating a number of strategic options open to the Company to maximise value for shareholders.  Options include securing long term strategic partners for the business and may include an offer being made for the Company.  The Board is currently in discussion with a number of parties in Europe and North America. The significant contract revenues announced on 17 January have strengthened the Company's position in this regard.

 

"The process remains ongoing but the Board is confident of a positive outcome in due course. The Board will continue to keep shareholders updated on progress."

   

 

-Ends-

 

 

For further information, please contact:

Evocutis plc


Tom Bannatyne, Chairman

+44 (0) 844 209 8440

Dr Gwyn Humphreys, Chief Executive Officer

www.evocutis.com

 

Zeus Capital Limited


Andrew Jones

Tel: +44 (0) 161 831 1512

Nick Cowles

www.zeuscapital.co.uk

 

 

XCAP Securities Plc


Halimah Hussain / Adrian Kirk

Tel: +44 (0) 207 101 7070        


www.xcapgroup.co.uk

 

Media enquiries:

Abchurch Communications


Sarah Hollins / Adam Michael / Simone Elviss / Jamie Hooper

Tel: +44 (0) 20 7398 7719

jamie.hooper@abchurch-group.com

www.abchurch-group.com

 

 

Notes to editors

 

About Evocutis plc

 

With a rich portfolio of new product opportunities, Evocutis offers antimicrobial and dermatological expertise to the cosmetic, consumer healthcare and pharmaceutical industries. Being uniquely able to combine research for laboratory testing, advanced skin models and clinical testing, Evocutis offers a complete service for the development of skin care products and ingredients. Through research and testing Evocutis enables its clients to advance the discovery of skin care products that actually work.

 

Offering high quality contract research services, Evocutis specialises in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research. Unique characteristics of its colonised full thickness model of human skin (LabSkin™) allow rapid, cost effective screening of, for example, anti-ageing, anti-inflammatory and antimicrobial ingredients and products for use on skin. 

  

When it comes to advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, the Evocutis focus is simple: intelligent and specialised R&D input.

 

For further information, please see www.evocutis.com

 

 

About LabSkin™

 

LabSkin™ is an animal-replacement technology, that emulates living skin tissue and is a high value research and product testing tool for the cosmetic and healthcare industries. It is a full thickness human skin model, comprised of both dermal and epidermal layers, and is produced exclusively and reproducibly on site at Evocutis from primary human cells (keratinocytes & fibroblasts). The model exhibits a fully differentiated epidermal layer, which provides a completely dry surface for tailored testing requirements.

 

LabSkin™ is highly versatile, and alongside its antimicrobial model, Evocutis is developing models to test anti-ageing and moisturising products. The antimicrobial LabSkin™ model allows testing using pathogenic microorganisms which would not be possible in human clinical studies. In addition, methods have been developed to allow LabSkin™ to be inoculated with skin washings taken directly from human skin, thus providing a step-change in the quality of data possible from a laboratory model. By benchmarking activity against best-in-class products, the activity of new ingredients and formulations can be assessed for several antimicrobial endpoints, including immediate kill, rate of kill and residual activity.

 

Recent research indicates that our natural microflora is an integral part of our skin and makes a significant contribution to skin health. LabSkin™ provides a unique living skin surface which is validated for microbial applications and can simultaneously provide information on irritation, penetration, barrier function and skin structure.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMZELFLXFFEBBD
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


AGM Statement - RNS